Jacques Galipeau, MD, is the inaugural associate dean for therapeutics development at the University of Wisconsin School of Medicine and Public Health.
Galipeau, the Don and Marilyn Anderson Professor in Oncology, is the director of the Program for Advanced Cell Therapy. The program's mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults.
A board-certified hematologist, Galipeau earned his medical degree from the University of Montreal and completed an internal medicine residency at McGill University. He went on to complete a hematology-oncology fellowship at Tufts University and postdoctoral training in gene therapy at St. Jude Children's Hospital in Memphis, Tennessee.
Before arriving at the School of Medicine and Public Health in 2016, Galipeau was a faculty member at McGill University and Emory University, where he was a professor of hematology and oncology and director of the Emory Personalized Immunotherapy Center.
Galipeau has initiated and developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in translational development of cell therapies and the sponsor of a series of FDA-sanctioned clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn’s disease and graft vs. host disease. He has also developed the field of fusion engineered cytokines, known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer.